A novel in-frame GFAP p.E138_L148del mutation in Type II Alexander disease with atypical phenotypes

Eur J Hum Genet. 2022 Jun;30(6):687-694. doi: 10.1038/s41431-022-01073-2. Epub 2022 Mar 4.

Abstract

Alexander disease (AxD) is a neurodegenerative astrogliopathy caused by mutation in the glial fibrillary acidic protein (GFAP) gene. A 42-year-old Korean man presented with temporary gait disturbance and psychiatric regression after a minor head trauma in the absence of bulbar symptoms and signs. Magnetic resonance images of the brain and spinal cord showed significant atrophy of the medulla oblongata and the entire spinal cord as well as contrast-enhanced T2 hypointensity in the basal ganglia. DNA sequencing revealed a novel 33-bp in-frame deletion mutation (p.Glu138_Leu148del) within the 1B rod domain of GFAP, which was predicted to be deleterious by PROVEAN analysis. To test whether the deletion mutant is disease-causing, we performed in vitro GFAP assembly and sedimentation assays, and GFAP aggregation assays in human adrenal carcinoma SW13 (Vim-) cells and rat primary astrocytes. All the assays revealed that GFAP p.Glu138_Leu148del is aggregation prone. Based on these findings, we diagnosed the patient with Type II AxD. This is a report that demonstrates the pathogenicity of InDel mutation of GFAP through functional studies. This patient's atypical presentation as well as the discrepancy between clinical symptoms and radiologic findings may extend the scope of AxD.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alexander Disease* / diagnosis
  • Alexander Disease* / genetics
  • Alexander Disease* / pathology
  • Animals
  • Brain / metabolism
  • Glial Fibrillary Acidic Protein / genetics
  • Humans
  • Mutation
  • Phenotype
  • Rats

Substances

  • Glial Fibrillary Acidic Protein